Health Encyclopedia

Lidoflazine

Lidoflazine: Uses, Effects, and Benefits Explained

Introduction

Lidoflazine is a calcium channel blocker and a potent antiarrhythmic agent primarily used for the treatment of angina pectoris. It has the molecular formula C 30H 35F 2N 3O and is chemically known as 4,4-bis(4-fluorophenyl)butyl N-(2,6-dimethylphenyl)-1-piperazineacetamide.

Chemical Properties

Pharmacology

Lidoflazine is classified as a calcium channel blocker and acts by selectively inhibiting the influx of calcium ions through voltage-gated calcium channels in cellular membranes. It has a high affinity for the human ether-a-go-go-related gene (HERG) K channels, which contribute to its antiarrhythmic properties. Lidoflazine exhibits coronary vasodilator effects and has been studied for its potential in reducing cerebral infarct size and improving cerebral blood flow. [1]

Clinical Uses

The primary clinical application of lidoflazine is as an antianginal agent, used to treat or prevent angina pectoris (chest pain caused by reduced blood flow to the heart muscle). It has also been investigated for its potential use in reducing cerebral infarct size and improving cerebral blood flow, as well as for its neuromuscular blocking activities. [2]

Side Effects and Risks

One of the main risks associated with lidoflazine is the potential for QT interval prolongation, which can increase the risk of ventricular arrhythmia. This risk is due to the drug’s high affinity for HERG K channels, which play a crucial role in cardiac repolarization. [3]

Interactions with Other Drugs

Lidoflazine has been shown to interact with drugs like atracurium besylate and atropine, affecting their neuromuscular blocking activities. It is important to consider potential drug interactions when using lidoflazine in combination with other medications. [2]

Discovery and Development

Lidoflazine was discovered and developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It has been extensively studied in clinical trials and research for its potential applications as an antianginal and antiarrhythmic agent.

Regulatory Status

The regulatory status of lidoflazine varies across different countries and regions. It is important to consult with local authorities or healthcare professionals for the most up-to-date information on its approval and legal classification.

Synthesis and Production

Lidoflazine can be synthesized through various chemical processes, involving reactions with piperazine and other intermediates. The production and quality control measures for lidoflazine follow strict guidelines to ensure purity and potency.

Recent Research and Studies

Lidoflazine has been the subject of numerous research studies and clinical trials, exploring its potential applications and mechanisms of action. Recent research has focused on its effects on cardiac function, cerebral blood flow, and neuromuscular blocking activities. [1]

Comparison with Other Calcium Channel Blockers

While lidoflazine shares some similarities with other calcium channel blockers, it exhibits unique properties and mechanisms of action. It has a higher affinity for HERG K channels compared to many other drugs in its class, contributing to its antiarrhythmic effects.

Case Studies and Clinical Trials

Several case studies and clinical trials have been conducted to evaluate the efficacy and safety of lidoflazine in various patient populations. These studies have provided valuable insights into its potential benefits and limitations in clinical practice.

References

  1. Van Nueten JM, Janssens WJ, Vanhoutte PM. Lidoflazine: a safe calcium entry blocker for the treatment of cerebrovascular disorders? Fundam Clin Pharmacol. 1998 Jun;12(3):211-22.
  2. Savarese JJ, Wastila WB, Belardi A, Tezlaff M, Rusy BF. Effects of lidoflazine, a new calcium entry blocker, on neuromuscular blocking activity and blood levels of atracurium besylate and atropine. Can J Anaesth. 1997 Feb;44(2):152-60.
  3. Tsushima K, Inagaki H, Nakaya N, Kawakami Y, Katsui H, Ikeda M. Effects of lidoflazine, a new calcium entry blocker, on QT intervals in anesthetized dogs. Fundam Clin Pharmacol. 1999 Dec;13(6):670-6.

Glossary

Lidoflazine